Efficient Cell Cryopreservation Media
Isis Project No 4026 Oxford researchers have developed cell cryopreservation media with well-defined, serum free agents for preserving adult stem cells, human and animal primary cells.
The market size of stem cell research products is estimated to be $800M and expanding through double-digit growth each year (Stem cell research products, by Bharat Book Bureau, 2008). The market of cell therapy including stem cell therapy is even greater. Oxford researchers have developed cryopreservation reagents supported by data and comprehensive analysis, and the reagents could enable stem cell researchers, pharmaceutical companies and clinicians to meet cell cryopreservation needs. The intellectual property also covers human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells.
The Oxford Invention
For clinical applications of cell therapy including stem cell therapy, cryopreservation is critical for both storage and off-the-shelf product offerings. Well-defined, serum free cryoprotecting agents (CPAs) are necessary for obtaining regulatory approval. Low DMSO concentrations are also desirable. The Oxford invention is an improved cryopreservation media containing well-defined CPAs, which could avoid infection risks and could be acceptable to cryopreserve cells being introduced to a human body. It also contains low levels of DMSO, but maintains high cell viability and reduces cell doubling time. In some cases it improves cell viability. Such efficient Oxford cell cryopreservation media can be equally applied to cryopreservation of animal cells and animal stem cells.
This Oxford invention is the subject of a patent application, and Isis is keen to talk to companies interested in developing the commercial opportunity. Please contact the Isis Project Manager.
Type of Offer:
« More Genetics Patents« More Medical Patents